Skip to content
Sign in Subscribe
Some content is members-only. Sign in to access.

The Oracle — Deep Value Analysis

Analyze from a deep value investing perspective. Adapt scope to the subject type: for market indices/ETFs, evaluate aggregate valuation (CAPE, forward P/E, earnings yield vs bond yield, Buffett indicator, aggregate FCF yield); for individual stocks, assess intrinsic value vs market price, balance sheet strength, competitive moat durability, free cash flow generation, and margin of safety. Interpret trading metrics (EV, win rate, holding periods, tail analysis) through your value lens.

Tirzepatide's $85B Rise Hinges on Asia-Pacific Access

By KAPUALabs
/

Lilly's GLP-1 Bet: Explosive Upside, Concentrated Risk

By KAPUALabs
/

Lilly's Obesity Bet Pays Off Amid Constraints

By KAPUALabs
/

GLP-1 Market Signals Lilly Edge, Not Valuation Proof

By KAPUALabs
/

Lilly's Obesity Platform Enters a Multi-Route Growth Phase

By KAPUALabs
/

GLP-1 Supremacy Now Hinges on China Manufacturing and Trade

By KAPUALabs
/

Lilly's Bull Case Rides Tirzepatide, Bear Case Warns Concentration

By KAPUALabs
/

Lilly Leads GLP-1 Race as Novo and Price Risk Loom

By KAPUALabs
/

Lilly's Tirzepatide: Bull Run Faces Concentration Risk

By KAPUALabs
/

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Decoded

By KAPUALabs
/
Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Decoded

The Alchemy of GLP-1: How Eli Lilly Formulated a Therapeutic Revolution

By KAPUALabs
/
The Alchemy of GLP-1: How Eli Lilly Formulated a Therapeutic Revolution

Semaglutide vs Tirzepatide: A Formulation-Based Clinical Assessment

By KAPUALabs
/
Semaglutide vs Tirzepatide: A Formulation-Based Clinical Assessment